Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The gut microbiome and metabolic syndrome
Kruttika Dabke, … , Gustaf Hendrick, Suzanne Devkota
Kruttika Dabke, … , Gustaf Hendrick, Suzanne Devkota
Published October 1, 2019
Citation Information: J Clin Invest. 2019;129(10):4050-4057. https://doi.org/10.1172/JCI129194.
View: Text | PDF
Review Series

The gut microbiome and metabolic syndrome

  • Text
  • PDF
Abstract

The metabolic syndrome (MetS) is a constellation of risk factors that, if left untreated, will often progress to greater metabolic defects such as type 2 diabetes and nonalcoholic fatty liver disease. While these risk factors have been established for over 40 years, the definition of MetS warrants reconsideration in light of the substantial data that have emerged from studies of the gut microbiome. In this Review we present the existing recent literature that supports the gut microbiome’s potential influence on the various risk factors of MetS. The interplay of the intestinal microbiota with host metabolism has been shown to be mediated by a myriad of factors, including a defective gut barrier, bile acid metabolism, antibiotic use, and the pleiotropic effects of microbially produced metabolites. These data show that events that start in the gut, often in response to external cues such as diet and circadian disruption, have far-reaching effects beyond the gut.

Authors

Kruttika Dabke, Gustaf Hendrick, Suzanne Devkota

×

Figure 1

A model for the gut microbiome’s interaction with the intestinal epithelial barrier and its contribution to metabolic diseases.

Options: View larger image (or click on image) Download as PowerPoint
A model for the gut microbiome’s interaction with the intestinal epithel...
From the top: High-fat, low-fiber diet induces intestinal dysbiosis, resulting in aberrant metabolite concentrations that disrupt GLP-2–mediated tight junction integrity. This loss of integrity makes the gut epithelium more permissive to microbial lipopolysaccharide (LPS), trimethylamine (TMA), and other metabolites entering the circulation and contributing to the chronic inflammation of liver and adipose tissue that is associated with the development of cardiovascular disease, insulin resistance, and other conditions associated with the metabolic syndrome.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts